Generic vs. Brand-Name Ketamine Options

Ketamine brand and generic name options fall into four main categories: Ketalar, the original brand-name injectable ketamine hydrochloride; generic ketamine injection, the bioequivalent version used in most IV infusion clinics; Spravato (esketamine), an FDA-approved nasal spray for treatment-resistant depression; and compounded ketamine tablet, troche, or capsule formulations prepared by compounding pharmacies for oral use. Patients often hear these names used interchangeably, but they represent different molecules, different FDA approval pathways, and different costs and administration settings. This guide breaks down what separates each ketamine brand and generic name option and how that affects treatment access, insurance coverage, and where a patient can take the medication.

The Ketamine Product Landscape

Ketamine-based treatments split into five distinct product types, each with its own regulatory status:

• Ketalar, the original brand-name injectable ketamine hydrochloride
• Generic ketamine hydrochloride injection, bioequivalent to Ketalar and used in IV infusion clinics and hospitals
• Spravato (esketamine), an FDA-approved nasal spray containing only the S-enantiomer of ketamine
• Compounded ketamine tablet, troches, or capsules, custom-prepared by compounding pharmacies for oral use
• Compounded injectable ketamine, sometimes used in clinic settings for intramuscular (IM) injection or infusion

Ketalar: The Original Brand

Ketalar is the trade name for injectable ketamine hydrochloride, developed by Parke-Davis and approved by the FDA in 1970 as a general anesthetic. It is manufactured as a solution for injection in concentrations of 10 mg/mL, 50 mg/mL, and 500 mg/mL, sold in 10 mL and 20 mL vials. Ketamine hydrochloride's molecular structure and pharmacological data are documented in the PubChem compound database. Ketalar remains on the market today, though generic versions now account for most of the ketamine supplied to hospitals and outpatient infusion clinics.

Key facts about Ketalar:

• Racemic mixture containing equal parts R-ketamine and S-ketamine
• FDA-approved only for anesthetic use; psychiatric use is off-label
• Manufactured under FDA current Good Manufacturing Practice (cGMP) standards
• Price varies significantly by market and hospital procurement contract

Generic Ketamine Injection

Generic ketamine injection is the ketamine hydrochloride product most commonly used in IV infusion clinics for psychiatric treatment, and it is what most patients receive when a clinic says "ketamine infusion" without specifying Ketalar by name. After Ketalar's patent protection expired, manufacturers received FDA approval for generic versions through the Abbreviated New Drug Application (ANDA) process, which requires demonstrated bioequivalence to Ketalar as the reference listed drug.

Generic ketamine injection appears in:

• Hospital anesthesia departments
• Emergency departments
• IV ketamine infusion clinics for psychiatric treatment
• Procedure suites for sedation

Generic ketamine injection must meet FDA bioequivalence standards and contains the same active ingredient and concentration as Ketalar, manufactured under cGMP oversight, and it is significantly less expensive than the Ketalar brand, which is why it dominates clinical supply. See how this route compares to oral options in our oral vs. IV ketamine comparison.

Spravato (Esketamine): A Different Molecule

Spravato, manufactured by Janssen Pharmaceuticals, is chemically distinct from racemic ketamine. It contains only esketamine, the S(+) enantiomer of ketamine, delivered as a nasal spray under a restricted distribution program.

Why Esketamine?

Ketamine works primarily as an NMDA receptor antagonist, a drug that blocks N-methyl-D-aspartate receptors in the brain involved in mood regulation and pain signaling. The two enantiomers of ketamine bind these receptors differently. S-ketamine (esketamine) is approximately 3 to 4 times more potent at NMDA receptors than R-ketamine, while R-ketamine has less NMDA activity and may work through different antidepressant mechanisms with a more favorable dissociative side effect profile, according to StatPearls' clinical reference on ketamine pharmacology. Janssen selected the S-enantiomer for Spravato based on its higher potency, which allows lower doses, and because isolating it enabled patent protection for an otherwise off-patent molecule.

Spravato's FDA Approvals

The FDA approved Spravato in 2019 for treatment-resistant depression (TRD) in adults, defined as failure of two or more antidepressant trials. In 2020, the FDA added approval for major depressive disorder with acute suicidal ideation or behavior (MDD-SI). Read more in our esketamine for treatment-resistant depression guide.

The REMS Requirement

Spravato is dispensed exclusively through a Risk Evaluation and Mitigation Strategy (REMS) program, an FDA-mandated safety program required for certain drugs with serious risks. Patients cannot take Spravato at home. Every dose must be administered in a certified healthcare setting with two hours of post-administration monitoring. This is a fundamental operational difference from compounded ketamine tablet, which patients can often take at home under a prescriber's direction.

Spravato vs. Racemic Ketamine: Is One Better?

This remains a matter of scientific debate. Spravato's FDA approval gives it a regulatory and insurance advantage over off-label racemic ketamine. However, no head-to-head randomized trial has directly compared esketamine to racemic ketamine for depression, and the clinical evidence base for racemic IV ketamine is larger. Some researchers suggest R-ketamine may produce more durable antidepressant effects with less dissociation, though this has not been confirmed in large controlled trials.

Compounded Ketamine Tablet: The Off-Label Oral Standard

For patients seeking oral ketamine, compounded ketamine tablet, troche, or capsule formulations are currently the only option, since no manufacturer sells an FDA-approved oral ketamine product. Compounding pharmacies, which prepare customized medications for individual patients under a prescriber's order, make ketamine in oral forms not available from pharmaceutical manufacturers:

• Troches or lozenges, the form most commonly prescribed for psychiatric use, covered in more detail in our guide to what ketamine troches are
• Tablets or capsules, used for daily maintenance or pain protocols
• Oral solutions, used when precise dose titration is needed

Compounded ketamine tablet uses the same ketamine hydrochloride active pharmaceutical ingredient as Ketalar, sourced as pharmaceutical-grade powder from DEA-registered suppliers. The difference lies in formulation, since it is converted to an oral form, and in scale, since it is compounded for individual patients rather than mass-produced. For a fuller breakdown of how compounded oral ketamine is made and prescribed, see our ketamine tablet overview.

Cost Comparison

Insurance coverage is one of the biggest practical differences between these products. Our guide on the insurance coverage gap for oral ketamine tablets covers why compounded formulations are usually paid out of pocket while Spravato often qualifies for prior authorization.

Who Typically Uses Each Option

Generic IV ketamine infusion suits patients needing a rapid acute antidepressant effect, severe treatment-resistant depression, or those who have not responded to oral forms. It has the largest evidence base for acute depression treatment.

Spravato suits patients with documented TRD who have insurance coverage and can attend twice-weekly in-clinic administration initially under REMS requirements. It is currently the most insurance-accessible option.

Compounded ketamine tablet suits patients seeking home-based maintenance therapy, those unable to access infusion clinics regularly, patients on chronic pain protocols, or those who responded to IV ketamine and need maintenance dosing between sessions.

Compounded IM ketamine is sometimes used in clinics as a lower-cost alternative to IV infusion, with bioavailability generally cited around 90 to 95 percent.

Compounded S-Ketamine: A Separate Category

Some compounding pharmacies offer S-ketamine (esketamine) in oral formulations that are distinct from Spravato. This compounded S-ketamine is not FDA-approved and does not fall under the Spravato REMS program. Its clinical advantages over compounded racemic ketamine tablet have not been established in oral formulations, so patients should discuss the evidence directly with their prescriber before choosing it over standard racemic compounded ketamine.